跳至主要内容
临床试验/CTRI/2025/12/099604
CTRI/2025/12/099604尚未招募不适用

A Comparative study of efficacy, safety and tolerance of Olmesartan medoxomil and Azilsartan medoxomil in newly diagnosed patients with stage 1 Hypertension -A prospective observational open label study.

Self1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年4月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
100
试验地点
1

研究概览

简要总结

This study is randomized,open label,parralel group ,prospective study comparing the safety efficacyand tolerance of Olmesartan medoxomil 20 mg OD and Azilsartan medoxomil 40 mg OD for 3 months in 100 patients in a tertiary care centre in salem,Taminadu,India.Primary end point is reduction in both systolic and diastolic BP <140/90mmHg at the end of 1st ,2nd and 3rd month.Secondary end point is to record adverse effects of Olmesartan and Azilsartan such as dizziness, fatigue, headache, hyperglycemia.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Patients of both sexes aged more than 18 years with stage 1 hypertension (140-159 systolic BP/90-99 diastolic BP).
  • Patients with associated co-morbid conditions as diabetes, hypothyroidism without complications.
  • Patients who are willing to give consent for the study.

排除标准

  • Patients with stage ll and lll hypertension.
  • Patients already on anti-hypertensive medications.
  • Patients with hypertensive urgencies and emergencies.
  • Along with additional comorbid diseases like coronary artery disease CCF, CKD, stroke and heart, kidney, liver complications.
  • Pregnant and lactating women.

研究者

发起方
Self
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Kaviya M

Vinayaka Missions Research Foundation

研究点 (1)

Loading locations...

相似试验